scholarly article | Q13442814 |
P50 | author | Shinji Hatakeyama | Q73231795 |
P2093 | author name string | Kazutaka Ikeda | |
Ryo Taguchi | |||
Yukio Ishikawa | |||
Hiroyasu Sato | |||
Kei Yamamoto | |||
Makoto Murakami | |||
Shuntaro Hara | |||
Yoshitaka Taketomi | |||
Hiroyuki Itabe | |||
Kae Tsutsumi | |||
Ichiro Kudo | |||
Toshiharu Ishii | |||
Tetsuyuki Kobayashi | |||
Yuki Isogai | |||
Rina Kato | |||
Seiko Masuda | |||
Mitsuhiro Ohtsuki | |||
Joe Yamada | |||
Go-ichi Saka | |||
P2860 | cites work | Novel human secreted phospholipase A(2) with homology to the group III bee venom enzyme | Q22253324 |
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology | Q24317282 | ||
Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice | Q24563208 | ||
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION | Q25939000 | ||
Efficient selection for high-expression transfectants with a novel eukaryotic vector | Q27860810 | ||
Expression and characterization of human group V phospholipase A2 | Q28285021 | ||
Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity | Q28291085 | ||
Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor | Q28509942 | ||
Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms | Q28564979 | ||
The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2 | Q28565225 | ||
Phospholipase A2 enzymes | Q28609770 | ||
The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
Bee venom phospholipase A2 induces stage-specific growth arrest of the intraerythrocytic Plasmodium falciparum via modifications of human serum components | Q30926042 | ||
Mammalian lysophospholipases. | Q33681195 | ||
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease | Q33874567 | ||
Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. | Q33947290 | ||
Increased platelet deposition on atherosclerotic coronary arteries | Q34125013 | ||
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. | Q34129390 | ||
Cellular arachidonate-releasing function of novel classes of secretory phospholipase A2s (groups III and XII). | Q34169715 | ||
Diversity and regulatory functions of mammalian secretory phospholipase A2s. | Q34212477 | ||
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation | Q34298659 | ||
The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia | Q34313013 | ||
Phospholipase A(2) in vascular disease | Q34339322 | ||
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice | Q34598093 | ||
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. | Q35029268 | ||
Stimulated arachidonate metabolism during foam cell transformation of mouse peritoneal macrophages with oxidized low density lipoprotein | Q35586059 | ||
Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis | Q35677082 | ||
Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells | Q35822759 | ||
Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity | Q35828524 | ||
Expression of intercellular adhesion molecule-1 in atherosclerotic plaques | Q35830615 | ||
Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia | Q36103315 | ||
Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model | Q36229287 | ||
Lysophosphatidic acid induces neointima formation through PPARgamma activation. | Q36402330 | ||
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. | Q36459773 | ||
Inflammation and atherosclerosis: novel insights into plaque formation and destabilization | Q36495025 | ||
Innate immunity, macrophage activation, and atherosclerosis | Q36938635 | ||
Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate | Q37354905 | ||
Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice | Q37511097 | ||
Practical methods for plasma lipoprotein analysis | Q38487562 | ||
The picomole determination of free and total cholesterol in cells in culture | Q39601488 | ||
The potent anti-Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. | Q39759518 | ||
Human group III phospholipase A2 suppresses adenovirus infection into host cells. Evidence that group III, V and X phospholipase A2s act on distinct cellular phospholipid molecular species | Q40057599 | ||
Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis | Q40137011 | ||
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. | Q40213725 | ||
Focused lipidomics by tandem mass spectrometry | Q40403203 | ||
Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2). | Q40428682 | ||
Cellular arachidonate-releasing function and inflammation-associated expression of group IIF secretory phospholipase A2. | Q40747061 | ||
Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells | Q40917338 | ||
Efficient gene activation system on mammalian cell chromosomes using recombinant adenovirus producing Cre recombinase | Q41149896 | ||
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. | Q41664283 | ||
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile | Q43837372 | ||
Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice | Q44079670 | ||
Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice | Q44176917 | ||
Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice | Q44316915 | ||
Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques | Q44529184 | ||
Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions | Q44628275 | ||
Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines | Q44641329 | ||
Rapid and selective identification of molecular species in phosphatidylcholine and sphingomyelin by conditional neutral loss scanning and MS3. | Q45164007 | ||
Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice | Q46560412 | ||
Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice | Q46573266 | ||
Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. | Q46669673 | ||
Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins | Q47942846 | ||
A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission | Q48952910 | ||
Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. | Q50760094 | ||
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. | Q52005910 | ||
Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2). | Q52544493 | ||
Impact of Phospholipase A2 group IIa gene polymorphism on phenotypic features of patients with familial adenomatous polyposis. | Q54450457 | ||
Role of cytosolic phospholipase A2 in allergic response and parturition | Q59069879 | ||
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5 , shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study | Q61560054 | ||
Nondenaturing polyacrylamide gradient gel electrophoresis | Q69553541 | ||
Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors | Q71612327 | ||
A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides | Q72465733 | ||
Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions | Q73623179 | ||
Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries | Q74471855 | ||
Expression of secretory phospholipase A2s in human atherosclerosis development | Q79922608 | ||
Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival | Q81294331 | ||
Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice | Q81317312 | ||
Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet | Q83118082 | ||
P433 | issue | 48 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lipoprotein | Q28350 |
atherosclerosis | Q12252367 | ||
macrophage | Q184204 | ||
P304 | page(s) | 33483-33497 | |
P577 | publication date | 2008-09-18 | |
P1433 | published in | Journal of Biological Chemistry | Q867727 |
P1476 | title | Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis | |
P478 | volume | 283 |
Q35776615 | A new era of secreted phospholipase A₂ |
Q36301300 | Acyl chain-dependent effect of lysophosphatidylcholine on cyclooxygenase (COX)-2 expression in endothelial cells |
Q34116412 | Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production |
Q34761280 | Acyl chain-dependent effect of lysophosphatidylcholine on endothelium-dependent vasorelaxation |
Q33706757 | Association between dairy intake, lipids and vascular structure and function in diabetes |
Q35125145 | Association between polymorphisms in phospholipase A2 genes and the plasma triglyceride response to an n-3 PUFA supplementation: a clinical trial |
Q26767063 | Bee Venom Phospholipase A2: Yesterday's Enemy Becomes Today's Friend |
Q33771533 | Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines |
Q88678092 | Comparative transcriptome analysis of rumen papillae in suckling and weaned Japanese Black calves using RNA sequencing |
Q50423667 | Diet-induced obesity alters the maternal metabolome and early placenta transcriptome and decreases placenta vascularity in the mouse. |
Q59050854 | Diverse Functions of Secretory Phospholipases A2 |
Q27340023 | Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme |
Q45728856 | Expression and localization of sPLA2-III in the rat CNS. |
Q92578258 | Group IID, IIE, IIF and III secreted phospholipase A2s |
Q42363727 | Group III phospholipase A2 promotes colitis and colorectal cancer |
Q24631144 | Group III secreted phospholipase A2 regulates epididymal sperm maturation and fertility in mice |
Q37257483 | Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation |
Q36727399 | Group X Secreted Phospholipase A2 Releases ω3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility |
Q34719753 | Hair follicular expression and function of group X secreted phospholipase A2 in mouse skin |
Q57293438 | Harmful and protective roles of group V phospholipase A: Current perspectives and future directions |
Q35590666 | In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2. |
Q35036028 | Integrated lipidomics in the secreted phospholipase A(2) biology |
Q34182618 | Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer |
Q58148425 | Lp-PLA2 et sPLA2 |
Q93052009 | Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells |
Q28510556 | Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis |
Q47128368 | Metabolic regulation by secreted phospholipase A2. |
Q37238669 | Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease |
Q38125279 | Molecular biology of atherosclerosis |
Q36681188 | Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL. |
Q27324083 | Oleoyl-lysophosphatidylcholine limits endothelial nitric oxide bioavailability by induction of reactive oxygen species |
Q41149645 | Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A2 in a spatial-specific manner |
Q26830664 | Phospholipase A2 enzymes and the risk of atherosclerosis |
Q26997377 | Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention |
Q43289695 | Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic |
Q34719758 | Physiological roles of group X-secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function |
Q37858911 | Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics |
Q33923169 | Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease |
Q38701624 | Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism. |
Q35385515 | Secretory phospholipase A₂ responsive liposomes |
Q37130793 | Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. |
Q33736168 | The (G>A) rs11573191 polymorphism of PLA2G5 gene is associated with premature coronary artery disease in the Mexican Mestizo population: the genetics of atherosclerotic disease Mexican study |
Q38987762 | The Roles of the Secreted Phospholipase A2 Gene Family in Immunology |
Q28586195 | The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity |
Q37435082 | The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo |
Q37334949 | The vicious circle between oxidative stress and inflammation in atherosclerosis. |
Q36394788 | Thyroid hormone status regulates the expression of secretory phospholipases |
Q34135420 | Varespladib methyl in cardiovascular disease |
Search more.